These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9855531)

  • 1. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Bramanti P; Sessa E; Rifici C; D'Aleo G; Floridia D; Di Bella P; Lublin F
    Neurology; 1998 Dec; 51(6):1720-3. PubMed ID: 9855531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.
    Pöllmann W; Erasmus LP; Feneberg W; Then Bergh F; Straube A
    Neurology; 2002 Aug; 59(4):636-9. PubMed ID: 12196668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects].
    Walther EU; Dietrich E; Hohlfeld R
    Nervenarzt; 1996 Jun; 67(6):452-6. PubMed ID: 8767199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of maintaining effective therapy in multiple sclerosis.
    Durelli L; Clerico M
    J Neurol; 2005 Sep; 252 Suppl 3():iii38-iii43. PubMed ID: 16170500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.
    Jeffery DR; Chepuri N; Durden D; Burdette J
    Mult Scler; 2005 Jun; 11(3):296-301. PubMed ID: 15957510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
    Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M;
    J Neurol; 2008 Sep; 255(9):1315-23. PubMed ID: 18825438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis.
    Leary SM; Thompson AJ
    J Neurol Neurosurg Psychiatry; 2004 Mar; 75(3):508-9. PubMed ID: 14966181
    [No Abstract]   [Full Text] [Related]  

  • 10. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
    Tremlett HL; Oger J
    Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis.
    Logan-Clubb L; Stacy M
    J Neurosci Nurs; 1995 Dec; 27(6):344-7. PubMed ID: 8770778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
    Cohen JA; Cutter GR; Fischer JS; Goodman AD; Heidenreich FR; Kooijmans MF; Sandrock AW; Rudick RA; Simon JH; Simonian NA; Tsao EC; Whitaker JN;
    Neurology; 2002 Sep; 59(5):679-87. PubMed ID: 12221157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early treatment and dose optimisation BENEFIT and BEYOND.
    Hartung HP
    J Neurol; 2005 Sep; 252 Suppl 3():iii44-iii50. PubMed ID: 16170501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis: side effects of interferon beta therapy and their management.
    Walther EU; Hohlfeld R
    Neurology; 1999 Nov; 53(8):1622-7. PubMed ID: 10563602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Formation of neutralizing antibodies in therapy of multiple sclerosis with interferon beta-1b. Practical procedure in suspected therapeutic failure].
    Walther EU; Dang T; Hartung HP; Hohlfeld R
    Nervenarzt; 1997 Dec; 68(12):935-9. PubMed ID: 9465334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Baum K;
    J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
    Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
    Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.
    Schwid SR; Goodman AD; Mattson DH
    Arch Neurol; 1997 Sep; 54(9):1169-90. PubMed ID: 9311363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.
    Blake G; Murphy S
    Neurology; 1997 Dec; 49(6):1747-8. PubMed ID: 9409387
    [No Abstract]   [Full Text] [Related]  

  • 20. Education and self-management of interferon beta-1b therapy for multiple sclerosis.
    Keating MM; Ostby PL
    J Neurosci Nurs; 1996 Dec; 28(6):350-2, 357-8. PubMed ID: 9007762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.